SG11202006431WA - Non-viral dna vectors and uses thereof for antibody and fusion protein production - Google Patents
Non-viral dna vectors and uses thereof for antibody and fusion protein productionInfo
- Publication number
- SG11202006431WA SG11202006431WA SG11202006431WA SG11202006431WA SG11202006431WA SG 11202006431W A SG11202006431W A SG 11202006431WA SG 11202006431W A SG11202006431W A SG 11202006431WA SG 11202006431W A SG11202006431W A SG 11202006431WA SG 11202006431W A SG11202006431W A SG 11202006431WA
- Authority
- SG
- Singapore
- Prior art keywords
- antibody
- fusion protein
- protein production
- viral dna
- dna vectors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862630676P | 2018-02-14 | 2018-02-14 | |
US201862630670P | 2018-02-14 | 2018-02-14 | |
US201862680092P | 2018-06-04 | 2018-06-04 | |
US201862680087P | 2018-06-04 | 2018-06-04 | |
PCT/US2019/018016 WO2019161059A1 (en) | 2018-02-14 | 2019-02-14 | Non-viral dna vectors and uses thereof for antibody and fusion protein production |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202006431WA true SG11202006431WA (en) | 2020-08-28 |
Family
ID=67619630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202006431WA SG11202006431WA (en) | 2018-02-14 | 2019-02-14 | Non-viral dna vectors and uses thereof for antibody and fusion protein production |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220042035A1 (zh) |
EP (1) | EP3752191A4 (zh) |
JP (1) | JP2021513355A (zh) |
KR (1) | KR20200120649A (zh) |
CN (1) | CN111818942A (zh) |
AU (1) | AU2019221642A1 (zh) |
BR (1) | BR112020016288A2 (zh) |
CA (1) | CA3091250A1 (zh) |
IL (1) | IL276469A (zh) |
MA (1) | MA51842A (zh) |
MX (1) | MX2020008470A (zh) |
PH (1) | PH12020551039A1 (zh) |
SG (1) | SG11202006431WA (zh) |
WO (1) | WO2019161059A1 (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021511047A (ja) * | 2018-01-19 | 2021-05-06 | ジェネレーション バイオ カンパニー | 無細胞合成から得ることができる閉端DNAベクターおよびceDNAベクターを得るためのプロセス |
WO2021046265A1 (en) * | 2019-09-06 | 2021-03-11 | Generation Bio Co. | Lipid nanoparticle compositions comprising closed-ended dna and cleavable lipids and methods of use thereof |
WO2021169167A1 (en) * | 2020-02-29 | 2021-09-02 | Nanjing GenScript Biotech Co., Ltd. | Method for treating coronavirus infections |
DE102020111571A1 (de) * | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
EP4127186A1 (en) * | 2020-03-24 | 2023-02-08 | Generation Bio Co. | Non-viral dna vectors and uses thereof for expressing gaucher therapeutics |
EP4189098A1 (en) | 2020-07-27 | 2023-06-07 | Anjarium Biosciences AG | Compositions of dna molecules, methods of making therefor, and methods of use thereof |
US20240066149A1 (en) * | 2021-01-12 | 2024-02-29 | Jcr Pharmaceuticals Co., Ltd. | Nucleic Acid Molecule Containing Incorporated Gene Encoding Fused Protein of Ligand and Protein Having Physiological Activity |
AU2022214822A1 (en) * | 2021-01-26 | 2023-08-17 | Kriya Therapeutics, Inc. | Vector constructs for delivery of nucleic acids encoding therapeutic anti-tnf antibodies and methods of using the same |
WO2023091708A1 (en) * | 2021-11-18 | 2023-05-25 | The Brigham And Women's Hospital, Inc. | Induced proteinopathy models |
US11993783B1 (en) * | 2023-03-27 | 2024-05-28 | Genecraft Inc. | Nucleic acid molecule comprising asymmetrically modified ITR for improving expression rate of inserted gene, and use thereof |
CN116549632A (zh) * | 2023-03-28 | 2023-08-08 | 中国人民解放军军事科学院军事医学研究院 | 抗Lingo-1抗体Opicinumab的新用途及针对新用途的药物 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2410828C (en) * | 2000-06-01 | 2012-01-24 | University Of North Carolina At Chapel Hill | Duplexed parvovirus vectors |
WO2003018771A2 (en) * | 2001-08-27 | 2003-03-06 | Genentech, Inc. | A system for antibody expression and assembly |
JP6091435B2 (ja) * | 2011-02-22 | 2017-03-08 | カリフォルニア インスティチュート オブ テクノロジー | アデノ随伴ウイルス(aav)ベクターを用いたタンパク質の送達 |
EP2500434A1 (en) * | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery |
US20170007719A1 (en) * | 2014-02-06 | 2017-01-12 | Genzyme Corporation | Compositions and methods for treating and preventing macular degeneration |
US10577627B2 (en) * | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
KR102336362B1 (ko) * | 2016-03-03 | 2021-12-08 | 보이저 테라퓨틱스, 인크. | 비-바이러스 유전자 전달을 위한 폐쇄형-말단 선형 듀플렉스 dna |
WO2019032102A1 (en) * | 2017-08-09 | 2019-02-14 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | LINEAR DUPLEX DNA, WITH CLOSED ENDS OF ADENO-ASSOCIATED VIRUSES AND USES THEREOF |
EP3679148A4 (en) * | 2017-09-08 | 2021-06-09 | Generation Bio Co. | LIPID NANOPARTICLE FORMULATIONS OF NON-VIRAL CAPSIDE-FREE DNA VECTORS |
WO2019051255A1 (en) * | 2017-09-08 | 2019-03-14 | Generation Bio Co. | CLOSED-ENDED DNA (CEDNA) MODIFIED |
WO2019079496A2 (en) * | 2017-10-18 | 2019-04-25 | Regenxbio, Inc. | FULLY HUMAN ANTIBODY-BASED THERAPEUTIC AGENTS HAVING POST-TRANSLATION MODIFICATION |
WO2019113310A1 (en) * | 2017-12-06 | 2019-06-13 | Generation Bio Co. | Gene editing using a modified closed-ended dna (cedna) |
JP2021511047A (ja) * | 2018-01-19 | 2021-05-06 | ジェネレーション バイオ カンパニー | 無細胞合成から得ることができる閉端DNAベクターおよびceDNAベクターを得るためのプロセス |
US20210054405A1 (en) * | 2018-03-02 | 2021-02-25 | Generation Bio Co. | Closed-ended dna (cedna) vectors for insertion of transgenes at genomic safe harbors (gsh) in humans and murine genomes |
-
2019
- 2019-02-14 MX MX2020008470A patent/MX2020008470A/es unknown
- 2019-02-14 BR BR112020016288-4A patent/BR112020016288A2/pt unknown
- 2019-02-14 CN CN201980013028.XA patent/CN111818942A/zh active Pending
- 2019-02-14 KR KR1020207024274A patent/KR20200120649A/ko unknown
- 2019-02-14 SG SG11202006431WA patent/SG11202006431WA/en unknown
- 2019-02-14 AU AU2019221642A patent/AU2019221642A1/en active Pending
- 2019-02-14 EP EP19753655.0A patent/EP3752191A4/en active Pending
- 2019-02-14 JP JP2020543344A patent/JP2021513355A/ja active Pending
- 2019-02-14 US US16/968,990 patent/US20220042035A1/en active Pending
- 2019-02-14 MA MA051842A patent/MA51842A/fr unknown
- 2019-02-14 WO PCT/US2019/018016 patent/WO2019161059A1/en unknown
- 2019-02-14 CA CA3091250A patent/CA3091250A1/en active Pending
-
2020
- 2020-07-03 PH PH12020551039A patent/PH12020551039A1/en unknown
- 2020-08-03 IL IL276469A patent/IL276469A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2019221642A1 (en) | 2020-07-09 |
EP3752191A4 (en) | 2021-12-22 |
RU2020130010A (ru) | 2022-03-14 |
MA51842A (fr) | 2020-12-23 |
EP3752191A1 (en) | 2020-12-23 |
IL276469A (en) | 2020-09-30 |
MX2020008470A (es) | 2020-09-25 |
JP2021513355A (ja) | 2021-05-27 |
CN111818942A (zh) | 2020-10-23 |
KR20200120649A (ko) | 2020-10-21 |
WO2019161059A1 (en) | 2019-08-22 |
BR112020016288A2 (pt) | 2020-12-15 |
US20220042035A1 (en) | 2022-02-10 |
CA3091250A1 (en) | 2019-08-22 |
PH12020551039A1 (en) | 2021-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276469A (en) | Non-viral DNA vectors and their uses for the production of antibody and fusion protein | |
IL279510A (en) | Progranulin-FC polypeptide fusion proteins and their uses | |
HK1257518A1 (zh) | 針對人白介素-2的免疫刺激性人源化單克隆抗體及其融合蛋白 | |
TWI799368B (zh) | 抗tl1a抗原結合蛋白及相關核酸、表現載體、宿主細胞、醫藥組合物、方法及用途 | |
EP3454832A4 (en) | GDF15 FUSION PROTEINS AND USES THEREOF | |
EP3287470A4 (en) | Novel recombinant bi-functional fusion protein and preparation and application therefor | |
IL279505A (en) | Chimeric transmembrane protein and its uses | |
EP3436576A4 (en) | CELL LINE FOR THE PRODUCTION OF RECOMBINANT PROTEIN AND / OR A RECOMBINANT VIRAL VECTOR | |
EP3280727A4 (en) | TYPE I AND SINGLE-ARM TYPE II RECEPTOR FUSION PROTEINS AND USES THEREOF | |
EP3880814A4 (en) | FUSION PROTEIN | |
EP3502143A4 (en) | BINDING PEPTIDE FOR THE CONSTRUCTION OF A FUSION PROTEIN | |
ZA202100125B (en) | Novel fusion protein specific for cd137 and pd-l1 | |
IL275691A (en) | Antibody-fused proteins with a single-site cytosine daminase | |
EP3275895A4 (en) | Neuropilin-1 specific binding peptide, fusion protein fused with same, and use thereof | |
EP3757218A4 (en) | MERGER PROTEIN | |
EP3976642A4 (en) | APOE ANTIBODIES, FUSION PROTEINS AND THEIR USES | |
EP3863657A4 (en) | BIFUNCTIONAL FUSION PROTEINS AND USES THEREOF | |
IL278102A (en) | Fusion proteins containing cd47 antibodies and cytokines | |
EP3668551A4 (en) | APOM FC FUSION PROTEINS AND USES THEREOF | |
SG11202101904UA (en) | Spd-1 variant - fc fusion proteins | |
SG11202104912SA (en) | Fusion protein and use thereof | |
EP3426289A4 (en) | ANTIGEN-BINDING FUSION PROTEINS WITH MODIFIED HSP70 DOMAINS | |
IL290715A (en) | nkg2d fusion proteins and their use | |
EP3849599A4 (en) | Pneumococcal fusion protein vaccines | |
ZA202102533B (en) | Fusion protein |